Sign in →

TEST ID MPO Myeloperoxidase Antibodies, IgG, Serum

Reporting Name

Myeloperoxidase Ab, S

Specimen Type

Serum


Additional Testing Requirements


To distinguish between microscopic polyangiitis and other forms of anti-neutrophil cytoplasmic antibody-associated vasculitis, also order PR3 / Proteinase 3 Antibodies, IgG, Serum and ANCA / Cytoplasmic Neutrophil Antibodies, Serum; alternatively, VASC / Antineutrophil Cytoplasmic Antibodies Vasculitis Panel, Serum may be ordered instead, which initially tests for myeloperoxidase and proteinase 3 antibodies, with reflex to ANCA when appropriate.



Specimen Required


Supplies: Sarstedt Aliquot Tube 5 mL (T914)

Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 0.5 mL

Collection Instructions: Centrifuge and aliquot serum into a plastic vial.


Specimen Minimum Volume

0.35 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 21 days
  Frozen  21 days

Method Name

Multiplex Flow Immunoassay

Reject Due To

Gross hemolysis Reject
Gross lipemia Reject
Gross icterus OK

Reference Values

<0.4 U (negative)

0.4-0.9 U (equivocal)

≥1.0 U (positive)

Reference values apply to all ages.

Day(s) Performed

Monday through Saturday

Report Available

2 to 4 days

Specimen Retention Time

14 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

CPT Code Information

83516

Forms

If not ordering electronically, complete, print, and send a Renal Diagnostics Test Request (T830) with the specimen.

Useful For

Evaluating patients with clinical features anti-neutrophil cytoplasmic antibody associated vasculitis, specifically granulomatosis with polyangiitis, microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis

 

Distinguishing between MPA and other forms of ANCA-associated vasculitis, in conjunction with proteinase 3 antibody and cytoplasmic neutrophil antibody testing

 

Following treatment response or monitoring disease activity in patients with myeloperoxidase (MPO) antibodies